Updated:
Co-Diagnostics, Inc.
Co-Diagnostics, Inc. is a other; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for private-markets...
Co-Diagnostics, Inc.
the Power to Know | MISSION STATEMENT
General information
Firm type
other
Frequently asked questions
Who runs investment decisions at Co-Diagnostics, Inc.?
Co-Diagnostics, Inc. is a publicly traded company, not a family office. Investment decisions are made by its executive leadership, including the CEO and board of directors, following corporate governance rules. No single family controls the firm's investment strategy.
How does Co-Diagnostics, Inc. source its intellectual property?
The company develops its own IP through internal R&D, primarily its Co-Primer technology platform. Patents covering the Co-Primer method are held by the firm and were developed by its founding scientific team. No external licensing arrangements have been publicly disclosed as primary sources.
Is Co-Diagnostics, Inc. structured as a family office or a biotech firm?
Co-Diagnostics, Inc. is a publicly traded molecular diagnostics company, not a family office. It is listed on the Nasdaq under CODX and operates with a corporate board and executive team. It does not manage external capital for family offices or institutional allocators.
What investment stages does Co-Diagnostics, Inc. typically target?
Co-Diagnostics, Inc. does not make investments; it is an operating company that develops and sells diagnostic tests. The firm's capital allocation is limited to R&D spending, manufacturing capacity, and strategic partnerships for geographic expansion.
Which sectors does Co-Diagnostics, Inc. explicitly avoid?
Co-Diagnostics, Inc. focuses exclusively on molecular diagnostics for infectious diseases. It does not operate in other healthcare sectors like therapeutics, medical devices, or patient services. No public statements have been made about specific sector avoidance.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: